# BOOSTER: ablation during continuing immunotherapy for limited residual lung cancer

Source: https://onco.cc/key-papers/paper-booster-ablation-immunotherapy-2025/  
OnCo record `paper-booster-ablation-immunotherapy-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This small randomised phase 2 trial found longer progression-free survival with ablation in selected lung cancer after an immunotherapy response. It did not test SBRT or establish one ablation method as universally best.

## Summary

Single-centre open-label trial in advanced non-small-cell lung cancer with limited residual disease after first-line anti-PD-1/PD-L1 treatment and no progression before randomisation. Sixty-five patients were allocated 2:1; the main analysis included 42 with ablation plus continuing immunotherapy and 20 with immunotherapy alone after three withdrawals. Eligible lung residual lesions were ablated; this was not treatment of every disease site.

The primary progression-free survival clock began at immunotherapy initiation, before randomisation. The main text also reports a separate analysis starting at randomisation. Keep those clocks and denominators separate when comparing estimates with another trial. The study enrolled fewer patients than planned and needs confirmation.

## Fields

- Kind: Key paper
- Last checked: 2026-11-09
- Tags: education-audit; local-treatment
- Journal: Signal transduction and targeted therapy
- Year: 2025
- DOI: 10.1038/s41392-025-02460-z
- Authors: Yang S, Liu X, Yu J, Chen X, Liu X, Zhao S, Jiang T, Sun H, Yang M, Wu F, Li A, Wang L, Gao G, Xu Y, Chen B, Ren S.
- Findings: Main analysis: median progression-free survival from immunotherapy initiation was 26.7 versus 11.7 months; hazard ratio 0.213, 95 percent confidence interval 0.099 to 0.461.; The report gives overall-survival hazard ratio 0.242, confidence interval 0.057 to 1.019 and nominal p=0.036, with medians not reached. The interval and reported test are retained together; the progression endpoint is not proof of a settled survival gain.; Ablation-related pneumothorax occurred in 15 of 42 patients, including one grade 3 event; pleural effusion occurred in 10 and bronchopulmonary haemorrhage in eight. These are study-group observations, not individual risk predictions.
- What it means: Provides a hypothesis-supporting result for this selected residual-lung-disease setting. It does not establish the same effect for breast cancer, oligoprogression, every local method or a proposed immune mechanism.
- Caveats: The 65 randomised patients and 62 in the main analysis are different denominators; supplementary all-randomised analyses were reported separately.; Cryoablation versus heating was exploratory, with differences in lesion characteristics and no multiple-comparison correction. It was not a randomised comparison of modalities.; Peripheral cytokine measurements came from a separate 97-patient cohort. They do not establish tumour-specific priming or explain the randomised treatment effect.; The abstract and figure/main-text thermal-subgroup counts differ. No corrected subgroup count or universal technique ranking is invented here.

## Sources

- Primary publication identity and abstract: https://pubmed.ncbi.nlm.nih.gov/41213939/
- Full report: methods, endpoint clocks, safety and subgroup limitations: https://pmc.ncbi.nlm.nih.gov/articles/PMC12603194/

## Connected records

- terms: [Systemic versus local therapy](https://onco.cc/terms/systemic-vs-local-therapy/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Thermal ablation (RFA, microwave, cryo)](https://onco.cc/technologies/thermal-ablation/)

---
JSON: https://onco.cc/api/v1/entities/paper-booster-ablation-immunotherapy-2025.json